NCT02387294View on ClinicalTrials.gov

Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Human Influenza
Interventions
BIOLOGICAL

Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml)

vaccination

BIOLOGICAL

Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)

vaccination

Sponsors
All Listed Sponsors
lead

Fluart Innovative Vaccine Ltd, Hungary

INDUSTRY